BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)

12.97
Delayed Data
As of 4:00pm ET
 -0.395 / -2.96%
Today’s Change
7.61
Today|||52-Week Range
19.99
-6.39%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.3B

Company Description

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.

Contact Information

BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard
Durham North Carolina 27703-8457
P:(919) 859-1302
Investor Relations:
(919) 859-7910

Employees

Shareholders

Other institutional45.50%
Mutual fund holders34.22%
Individual stakeholders12.56%

Top Executives

Jon P. StonehousePresident, Chief Executive Officer & Director
Michael L. JonesExecutive Director-Finance
Anthony DoyleChief Financial Officer
Helen M. ThackrayChief Research & Development Officer
Ryan ArnoldChief Medical Officer